Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.26)
# 4,349
Out of 5,056 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $43.52 | +10.29% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $12.00 | +150.00% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $104.17 | -25.12% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $29.00 | +37.93% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.92 | +2,401.63% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $43.52
Upside: +10.29%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $12.00
Upside: +150.00%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $104.17
Upside: -25.12%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $29.00
Upside: +37.93%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.92
Upside: +2,401.63%